We updated our model (New “Accumulate”, New € 5.1 TP) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while they claim “protecting long-term platform value”. The shift prioritizes Evoca NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commerci...
We will update our model (from “Buy” to “under review”) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while protecting long-term platform value. The shift prioritizes EVOCA NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commercialization r...
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...
Biotalys has entered into a strategic partnership with 21st.BIO to accelerate the production of Biotalys' protein-based biocontrol solutions. Biotalys indicated that this collaboration will leverage 21st.BIO's proprietary fermentation platform to support the production of Biotalys' AGROBODY agricultural biocontrol products at commercially competitive costs. We regret that Biotalys and Novonesis will conclude their collaboration (in line with the transition to this new agreement). Biotalys will...
MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in...
We reiterate our BUY rating but raise our target price from €35.0 to €43.0 driven by our increased estimates on the back of the strong membership momentum and the consolidation of Clever Fit, which in our view provides attractive upside potential. Note that we have not yet modelled in the potential savings from a change in business model for the 24/7 gyms in France, but we did include the VAT increase in Belgium. We also underline that BFIT remains on the ING Benelux Favourites list.
Basic-Fit: The Gym Group pre-close trading update / Fastned: 4Q25 preview / KPN: Vodafone new unlimited subscriptions with 1Gbps speed / Lotus Bakeries: Peer Lindt & Sprüngli FY25 sales / Ontex: Change in CEO brought forward and launch of a strategic review / Staffing sector: Page Group 4Q25 trading update / Zabka: Another miss on like-for-like growth.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.